Evaluating ChatGPT's efficacy in assessing the safety of non-prescription medications and supplements in patients with kidney disease.

Mohammad S SheikhErin F BarretoJing MiaoCharat ThongprayoonJames R GregoireBenjamin DreesmanStephen B EricksonIasmina M CraiciWisit Cheungpasitporn

Published in: Digital health (2024)

ChatGPT's capabilities in evaluating the safety of non-prescription drugs and supplements for kidney disease patients are modest compared to established drug information resources. Neither ChatGPT-3.5 nor ChatGPT-4 can be currently recommended as reliable drug information sources for this demographic. The results highlight the need for further improvements in the model's accuracy and reliability in the medical domain.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
peritoneal dialysis
health information
prognostic factors
drinking water
drug induced
emergency department
adverse drug
social media